Drug Search Results

Veliparib

Alternative Names: veliparib, abt-888
Latest Update: 2024-12-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: PARP Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Veliparib

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Breast Cancer|Ovarian Cancer|Non-Small-Cell Lung Cancer|Gliosarcoma|Squamous Cell Carcinoma|Triple Negative Breast Cancer|Peritoneal Cancer|Nose Cancer|Glioblastoma|Fallopian Tube Cancer

Phase 2: Colorectal Cancer|Astrocytoma|Head and Neck Cancer|Triple Negative Breast Cancer|Serous Cystadenocarcinoma|Breast Cancer|Mycosis Fungoides|Lymphoma, Non-Hodgkin|Large-Cell Immunoblastic Lymphoma|Glioblastoma|Brain Stem Cancer|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Testicular Cancer|B-Cell Marginal Zone Lymphoma|Gliosarcoma|Fallopian Tube Cancer|Ovarian Cancer|Acute Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia|Immunoblastic Lymphadenopathy|T-Cell Cutaneous Lymphoma|Melanoma|Oncology Unspecified|Glioma|Brain Cancer|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Squamous Cell Carcinoma|Burkitt Lymphoma|Large Cell Carcinoma|Oropharyngeal Cancer|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Plasmablastic Lymphoma|Hairy Cell Leukemia|Mantle-Cell Lymphoma|Sezary Syndrome|Intraocular Lymphoma|Hepatocellular Carcinoma|Extranodal NK-T-Cell Lymphoma|Adult T-Cell Leukemia-Lymphoma|Lymphomatoid Granulomatosis|Peritoneal Cancer|Leukemia, Plasma Cell|Large-Cell Anaplastic Lymphoma|T-Cell Peripheral Lymphoma|Multiple Myeloma|Waldenstrom Macroglobulinemia|Diffuse Large B-Cell Lymphoma|Chronic Lymphoid Leukemia|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Follicular Lymphoma|Chronic, Atypical, BCR-ABL Negative Myeloid Leukemia|Adenocarcinoma|Skin Cancer|Uterine Cancer|Cervical Cancer|Carcinoma, Adenosquamous|Myeloproliferative Disorders|Chronic Myeloid Leukemia|Oncology Solid Tumor Unspecified|Pancreatic Cancer|Myelodysplastic Syndrome|Myelofibrosis|Bronchiolo-Alveolar Adenocarcinoma|Juvenile Myelomonocytic Leukemia,|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Thrombocythemia, Essential|Myelodysplastic-Myeloproliferative Diseases|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Thrombocytosis|Neuroendocrine Carcinoma|Seminoma|Prostate Cancer|Polycythemia Vera

Phase 1: Vipoma|Malignant Carcinoid Syndrome|Lyme Disease|Carcinosarcoma|Peritoneal Cancer|Gastrinoma|Triple Negative Breast Cancer|Ovarian Cancer|Brenner Tumor|Thrombocytosis|Chromosome Disorders|Acute Myeloid Leukemia|Craniopharyngioma|Medulloblastoma|Acute Myelomonocytic Leukemia|Colorectal Cancer|Lung Cancer|Adrenocortical Adenoma|Islet Cell Adenoma|Prostate Cancer|Ependymoma|Adenocarcinoma|Renal Cell Carcinoma|Kidney Diseases|Multiple Endocrine Neoplasia Type 2b|Adrenocortical Carcinoma|Breast Cancer|Carcinoid Tumor|Carcinoma, Merkel Cell|Pancreatic Cancer|Pheochromocytoma|Glucagonoma|Islet Cell Carcinoma|Insulinoma|Neuroendocrine Tumors|Mucinous Adenocarcinoma|Fallopian Tube Cancer|Clear Cell Sarcoma|Medullary Carcinoma|Zollinger-Ellison Syndrome|Somatostatinoma|Transitional Cell Carcinoma|Mucinous Cystadenocarcinoma|Juvenile Myelomonocytic Leukemia,|Preleukemia|Brain Stem Cancer|Astrocytoma|Meningioma|Acute Megakaryoblastic Leukemia|Cervical Cancer|Carcinoma, Adenosquamous|Multiple Endocrine Neoplasia Type 2a|Multiple Endocrine Neoplasia Type 1|Adrenal Cortex Diseases|Hepatocellular Carcinoma|Neuroendocrine Carcinoma|Melanoma|Glioblastoma|Gastrointestinal Cancer|Fanconi Anemia|Endometrioid Carcinoma|Leukemia|Clear Cell Adenocarcinoma|Mixed Tumor, Mullerian|Lymphoma|Serous Cystadenocarcinoma|Acute Respiratory Distress Syndrome|Mouth Cancer|Chronic Myelomonocytic Leukemia|Male Breast Cancer|Esophageal Cancer|Oncology Solid Tumor Unspecified|Acute Lymphoid Leukemia|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Adult T-Cell Leukemia-Lymphoma|Chronic Myeloid Leukemia|Kidney Cancer|Brain Diseases|Liver Cancer|Bile Duct Cancer|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Chronic Lymphoid Leukemia|Acute Promyelocytic Leukemia|Adamantinoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Optic Nerve Glioma|Gallbladder Cancer|Cholangiocarcinoma|Subependymal Glioma|Ureteral Cancer|Acute Erythroblastic Leukemia|Non-Small-Cell Lung Cancer|Polycythemia Vera|Primitive Neuroectodermal Tumors|Rhabdoid Tumor|Head and Neck Cancer|Multiple Myeloma|Uterine Cancer|Thrombocythemia, Essential|Small Cell Lung Cancer|Lymphoma, Non-Hodgkin|Hereditary Breast and Ovarian Cancer Syndrome|Glioma|Ataxia Telangiectasia|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Myeloproliferative Disorders|Squamous Cell Carcinoma|Giant Cell Tumors|Embryonal Carcinoma|Bone Cancer|Experimental Melanoma|Mantle-Cell Lymphoma|T-Cell Lymphoma|Pinealoma|Oligodendroglioma|Testicular Cancer|Endometrial Cancer|Pancreatic Cyst|Liver Failure|Germinoma

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
NCI-2015-01912	P2	Active, not recruiting	Triple Negative Breast Cancer\|Brain Cancer	2025-03-15
NCI-2012-00864	P2	Active, not recruiting	Pancreatic Cancer\|Adenocarcinoma	2024-12-31
F131219003 (UAB 1372)	N/A	Active, not recruiting	Triple Negative Breast Cancer	2024-12-22
NCI-2011-01379	P2	Completed	Breast Cancer	2024-09-30

Recent News Events

Date	Type	Title
05/08/2024	PubMed	Veliparib exerts protective effects in intracerebral hemorrhage mice by inhibiting the inflammatory response and accelerating hematoma resolution.
05/05/2024	PubMed	High affinity and low PARP-trapping benzimidazole derivatives as a potential warhead for PARP1 degraders.
04/10/2024	PubMed	Spatiotemporal Concurrent PARP Inhibitor Sensitization Based on Radiation-Responsive Nanovesicles for Lung Cancer Chemoradiotherapy.
02/21/2024	News Article	PARP Inhibitors Market to reach over USD 10.31 billion by the year 2031 - Exclusive Report by InsightAce Analytic
09/05/2022	News Article	Sarcopenia Treatment Market exhibiting a CAGR of 5.9 % and is expected to reach USD 4,504 Million by 2029
11/02/2020	News Article	Non-Small Cell Lung Cancer Pipeline Expected to Offer Myriad of Novel Therapies in the Next Decade
05/21/2020	News Article	ASCO Annual Meeting to Highlight Clinical Oncology Findings from Seattle Cancer Care Alliance (SCCA)

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions